Maintenance therapy for CTCL: importance for prevention of disease progression

Emily R. Gordon, Megan H. Trager, Bradley D. Kwinta, Connor J. Stonesifer, Kaitlyn J. Lee, Oluwaseyi Adeuyan, Brigit A. Lapolla, Oleg E. Akilov, Paula A. Enz, Emmanuella Guenova, Pablo L. Ortiz-Romero, Evangelia Papadavid, Pietro Quaglino, Sima Rozati, Julia J. Scarisbrick, Thomas Litman, Larisa J. Geskin*

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

2 Citationer (Scopus)

Abstract

There are no established maintenance protocols for cutaneous lymphomas. We aim to determine patient treatments and outcomes during the COVID-19 pandemic in order to uncover the most effective maintenance protocols for cutaneous lymphomas and impact of treatment interruption. Data was collected retrospectively from nine international institutions, including 149 patients. Younger patients had earlier stages of disease and were most frequently treated with skin-directed therapies including topical steroids, mechlorethamine gel, and phototherapy. Treatment interruption varied by treatment type and stage, with patients on topical therapies and earlier stages of disease being least likely to experience interruption. Treatment interruption was significantly associated with progression of disease and worse outcomes, with twice as many patients progressing who had interruption compared to those without interruption. This study may demonstrate the significance of continuous maintenance therapies, even in younger patients with early stages of disease.

OriginalsprogEngelsk
TidsskriftLeukemia and Lymphoma
Vol/bind65
Udgave nummer12
Sider (fra-til)1883-1890
ISSN1042-8194
DOI
StatusUdgivet - 2024

Bibliografisk note

Publisher Copyright:
© 2024 Informa UK Limited, trading as Taylor & Francis Group.

Citationsformater